A Transnational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population
Status: Recruiting
Location: See all (21) locations...
Study Type: Observational
SUMMARY
A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese Population
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:
• Age 18 to 75 years of age
• acceptable FEV1 (according to ATS and ERS)
• compliance with study procedures All Asthma Cohorts
• physician diagnosed Asthma greater or equal to 3 months prior to screening visit
Locations
Other Locations
China
Research Site
NOT_YET_RECRUITING
Beijing
Research Site
NOT_YET_RECRUITING
Changsha
Research Site
RECRUITING
Chengdu
Research Site
NOT_YET_RECRUITING
Dongguan
Research Site
NOT_YET_RECRUITING
Foshan
Research Site
NOT_YET_RECRUITING
Guangzhou
Research Site
NOT_YET_RECRUITING
Hainan
Research Site
NOT_YET_RECRUITING
Hohhot
Research Site
NOT_YET_RECRUITING
Huizhou
Research Site
NOT_YET_RECRUITING
Kunming
Research Site
NOT_YET_RECRUITING
Nanjing
Research Site
NOT_YET_RECRUITING
Nanning
Research Site
NOT_YET_RECRUITING
Shanghai
Research Site
NOT_YET_RECRUITING
Shenyang
Research Site
RECRUITING
Taiyuan
Research Site
NOT_YET_RECRUITING
Wenzhou
Research Site
RECRUITING
Wuhan
Research Site
RECRUITING
Xi'an
Research Site
NOT_YET_RECRUITING
Xuzhou
Research Site
NOT_YET_RECRUITING
Zhanjiang
Research Site
NOT_YET_RECRUITING
Zhaoqing
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2024-01-08
Estimated Completion Date: 2026-10-08
Participants
Target number of participants: 355
Treatments
Cohort A
approximately 80 healthy participants
Cohort B
approximately 40 mild asthmatics on as-needed low dose inhaled corticosteroids (ICS)-formoterol, or low dose ICS plus as-needed short-acting β2 agonists (SABA), without the need for other controller medication.
Cohort C
approximately 160 moderate to severe asthmatics on low or medium dose ICS-long acting β2 agonists (LABA), high dose ICS alone or in combination with LABA .
Cohort D
approximately 75 asthmatics with protocol defined asthma exacerbation.
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca